Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma
Recent years have witnessed significant progress in the treatment of esophageal squamous-cell carcinoma (ESCC); however, the prognosis of ESCC is still unsatisfactory. Bio-markers are required to improve identification of high-risk populations and help management of ESCC. This study was to evaluate...
Gespeichert in:
| Veröffentlicht in: | OncoTargets and therapy 2018-01, Vol.11, p.8221-8226 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8226 |
|---|---|
| container_issue | |
| container_start_page | 8221 |
| container_title | OncoTargets and therapy |
| container_volume | 11 |
| creator | Chen, Lei You, Chuanwen Jin, Xiaowei Zhou, Lei Huang, Liyou Wang, Yanhua |
| description | Recent years have witnessed significant progress in the treatment of esophageal squamous-cell carcinoma (ESCC); however, the prognosis of ESCC is still unsatisfactory. Bio-markers are required to improve identification of high-risk populations and help management of ESCC. This study was to evaluate the role of serum CKAP4 in ESCC.
This longitudinal study recruited 207 ESCC patients and age-/sex-matched healthy controls. Circulating levels of CKAP4 were measured using ELISA kits, while the expression of CKAP4 in esophageal tissue was evaluated using Western blotting.
Serum CKAP4 levels were higher in ESCC patients (380.2±171.3 pg/mL) than healthy controls (271.8±97.4 pg/mL; |
| doi_str_mv | 10.2147/OTT.S183790 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6251352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A583695243</galeid><sourcerecordid>A583695243</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-8a32fe0b7dc9499047c04c8abb40c7597f1e4e76cd83b15bfd372e88596993973</originalsourceid><addsrcrecordid>eNptkt1rFDEUxQdR7Ic--S4BQQSZNZ-T5KVQFqtCoQ-uzyGTubObdibZJjOF_vdm6Vp3RfKQkPzuuTmXU1XvCF5QwuWXm9Vq8ZMoJjV-UZ0SIlXdaIZfHpxPqrOcbzFuGkX56-qEYcEU1-S08svHKeY7GGCKobY5R-ftBB3apjiBD4gjn5FFIT7AgDKk2Hm7DjFP3qHRpjtIqI8JQY7bjV2DLdD9bMc459rBMCBnk_MhjvZN9aq3Q4a3-_28-nX1dbX8Xl_ffPuxvLyuncByqpVltAfcys5prjXm0mHulG1bjp0UWvYEOMjGdYq1RLR9xyQFpYRutGZasvPq4kl3O7cjdA7ClOxgtsmX7z6aaL05fgl-Y9bxwTRUECZoEfi0F0jxfoY8mdHnnRcboNgylAhBGibwDv3wD3ob5xSKPUMppztIqb_U2g5gfOhj6et2ouZSKNZoQTkr1OI_VFkdjN7FAL0v90cFHw8KNmX00ybHYZ58DPkY_PwEuhRzTtA_D4Ngs4uQKREy-wgV-v3h_J7ZP5lhvwGQmcEF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242635088</pqid></control><display><type>article</type><title>Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Chen, Lei ; You, Chuanwen ; Jin, Xiaowei ; Zhou, Lei ; Huang, Liyou ; Wang, Yanhua</creator><creatorcontrib>Chen, Lei ; You, Chuanwen ; Jin, Xiaowei ; Zhou, Lei ; Huang, Liyou ; Wang, Yanhua</creatorcontrib><description>Recent years have witnessed significant progress in the treatment of esophageal squamous-cell carcinoma (ESCC); however, the prognosis of ESCC is still unsatisfactory. Bio-markers are required to improve identification of high-risk populations and help management of ESCC. This study was to evaluate the role of serum CKAP4 in ESCC.
This longitudinal study recruited 207 ESCC patients and age-/sex-matched healthy controls. Circulating levels of CKAP4 were measured using ELISA kits, while the expression of CKAP4 in esophageal tissue was evaluated using Western blotting.
Serum CKAP4 levels were higher in ESCC patients (380.2±171.3 pg/mL) than healthy controls (271.8±97.4 pg/mL;
<0.001). The area under the receiver-operating characteristic curve of serum CKAP4 levels to identify the presence of ESCC was 0.675 (95% CI 0.622-0.728;
<0.001). According to Youden's index, the best cutoff value was 429.1 pg/mL (sensitivity 0.415 and specificity 0.995). Furthermore, after follow-up, multivariate analyses identified that pathological lymph node metastases were the poorest prognostic factor (HR 1.862, 95% CI 1.093-3.173;
=0.022), followed by serum CKAP4 (HR 1.437, 95% CI 1.025-2.014;
=0.035). When stratified by tertiles of serum CKAP4, subjects in the first tertile presented a mean survival time of 75.4 months (95% CI 68.0-81.9), which decreased significantly in the second tertile (73.8 months, 95% CI 61.4-86.3) and the third tertile (59.9 months, 95% CI 49.8-70.0, log-rank
=8.235;
=0.016).
These results suggested that serum CKAP4 could be a potential biomarker for clinical management of ESCC.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S183790</identifier><identifier>PMID: 30538491</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Analysis ; Biological markers ; Cancer metastasis ; Cancer therapies ; Carcinoma ; Care and treatment ; Chemotherapy ; Cytoskeleton ; Disease ; Endoscopy ; Enzyme-linked immunosorbent assay ; Esophageal cancer ; Gene expression ; Health risk assessment ; Hospitals ; Lung cancer ; Medical prognosis ; Medical research ; Metastasis ; Original Research ; Ostomy ; Prognosis ; Proteins ; Proteomics ; Squamous cell carcinoma ; Systematic review</subject><ispartof>OncoTargets and therapy, 2018-01, Vol.11, p.8221-8226</ispartof><rights>COPYRIGHT 2018 Dove Medical Press Limited</rights><rights>2018. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 Chen et al. This work is published and licensed by Dove Medical Press Limited 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-8a32fe0b7dc9499047c04c8abb40c7597f1e4e76cd83b15bfd372e88596993973</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251352/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251352/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30538491$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>You, Chuanwen</creatorcontrib><creatorcontrib>Jin, Xiaowei</creatorcontrib><creatorcontrib>Zhou, Lei</creatorcontrib><creatorcontrib>Huang, Liyou</creatorcontrib><creatorcontrib>Wang, Yanhua</creatorcontrib><title>Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Recent years have witnessed significant progress in the treatment of esophageal squamous-cell carcinoma (ESCC); however, the prognosis of ESCC is still unsatisfactory. Bio-markers are required to improve identification of high-risk populations and help management of ESCC. This study was to evaluate the role of serum CKAP4 in ESCC.
This longitudinal study recruited 207 ESCC patients and age-/sex-matched healthy controls. Circulating levels of CKAP4 were measured using ELISA kits, while the expression of CKAP4 in esophageal tissue was evaluated using Western blotting.
Serum CKAP4 levels were higher in ESCC patients (380.2±171.3 pg/mL) than healthy controls (271.8±97.4 pg/mL;
<0.001). The area under the receiver-operating characteristic curve of serum CKAP4 levels to identify the presence of ESCC was 0.675 (95% CI 0.622-0.728;
<0.001). According to Youden's index, the best cutoff value was 429.1 pg/mL (sensitivity 0.415 and specificity 0.995). Furthermore, after follow-up, multivariate analyses identified that pathological lymph node metastases were the poorest prognostic factor (HR 1.862, 95% CI 1.093-3.173;
=0.022), followed by serum CKAP4 (HR 1.437, 95% CI 1.025-2.014;
=0.035). When stratified by tertiles of serum CKAP4, subjects in the first tertile presented a mean survival time of 75.4 months (95% CI 68.0-81.9), which decreased significantly in the second tertile (73.8 months, 95% CI 61.4-86.3) and the third tertile (59.9 months, 95% CI 49.8-70.0, log-rank
=8.235;
=0.016).
These results suggested that serum CKAP4 could be a potential biomarker for clinical management of ESCC.</description><subject>Analysis</subject><subject>Biological markers</subject><subject>Cancer metastasis</subject><subject>Cancer therapies</subject><subject>Carcinoma</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Cytoskeleton</subject><subject>Disease</subject><subject>Endoscopy</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Esophageal cancer</subject><subject>Gene expression</subject><subject>Health risk assessment</subject><subject>Hospitals</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Original Research</subject><subject>Ostomy</subject><subject>Prognosis</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Squamous cell carcinoma</subject><subject>Systematic review</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkt1rFDEUxQdR7Ic--S4BQQSZNZ-T5KVQFqtCoQ-uzyGTubObdibZJjOF_vdm6Vp3RfKQkPzuuTmXU1XvCF5QwuWXm9Vq8ZMoJjV-UZ0SIlXdaIZfHpxPqrOcbzFuGkX56-qEYcEU1-S08svHKeY7GGCKobY5R-ftBB3apjiBD4gjn5FFIT7AgDKk2Hm7DjFP3qHRpjtIqI8JQY7bjV2DLdD9bMc459rBMCBnk_MhjvZN9aq3Q4a3-_28-nX1dbX8Xl_ffPuxvLyuncByqpVltAfcys5prjXm0mHulG1bjp0UWvYEOMjGdYq1RLR9xyQFpYRutGZasvPq4kl3O7cjdA7ClOxgtsmX7z6aaL05fgl-Y9bxwTRUECZoEfi0F0jxfoY8mdHnnRcboNgylAhBGibwDv3wD3ob5xSKPUMppztIqb_U2g5gfOhj6et2ouZSKNZoQTkr1OI_VFkdjN7FAL0v90cFHw8KNmX00ybHYZ58DPkY_PwEuhRzTtA_D4Ngs4uQKREy-wgV-v3h_J7ZP5lhvwGQmcEF</recordid><startdate>20180101</startdate><enddate>20180101</enddate><creator>Chen, Lei</creator><creator>You, Chuanwen</creator><creator>Jin, Xiaowei</creator><creator>Zhou, Lei</creator><creator>Huang, Liyou</creator><creator>Wang, Yanhua</creator><general>Dove Medical Press Limited</general><general>Taylor & Francis Ltd</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180101</creationdate><title>Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma</title><author>Chen, Lei ; You, Chuanwen ; Jin, Xiaowei ; Zhou, Lei ; Huang, Liyou ; Wang, Yanhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-8a32fe0b7dc9499047c04c8abb40c7597f1e4e76cd83b15bfd372e88596993973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analysis</topic><topic>Biological markers</topic><topic>Cancer metastasis</topic><topic>Cancer therapies</topic><topic>Carcinoma</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Cytoskeleton</topic><topic>Disease</topic><topic>Endoscopy</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Esophageal cancer</topic><topic>Gene expression</topic><topic>Health risk assessment</topic><topic>Hospitals</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Original Research</topic><topic>Ostomy</topic><topic>Prognosis</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Squamous cell carcinoma</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Lei</creatorcontrib><creatorcontrib>You, Chuanwen</creatorcontrib><creatorcontrib>Jin, Xiaowei</creatorcontrib><creatorcontrib>Zhou, Lei</creatorcontrib><creatorcontrib>Huang, Liyou</creatorcontrib><creatorcontrib>Wang, Yanhua</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Lei</au><au>You, Chuanwen</au><au>Jin, Xiaowei</au><au>Zhou, Lei</au><au>Huang, Liyou</au><au>Wang, Yanhua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2018-01-01</date><risdate>2018</risdate><volume>11</volume><spage>8221</spage><epage>8226</epage><pages>8221-8226</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Recent years have witnessed significant progress in the treatment of esophageal squamous-cell carcinoma (ESCC); however, the prognosis of ESCC is still unsatisfactory. Bio-markers are required to improve identification of high-risk populations and help management of ESCC. This study was to evaluate the role of serum CKAP4 in ESCC.
This longitudinal study recruited 207 ESCC patients and age-/sex-matched healthy controls. Circulating levels of CKAP4 were measured using ELISA kits, while the expression of CKAP4 in esophageal tissue was evaluated using Western blotting.
Serum CKAP4 levels were higher in ESCC patients (380.2±171.3 pg/mL) than healthy controls (271.8±97.4 pg/mL;
<0.001). The area under the receiver-operating characteristic curve of serum CKAP4 levels to identify the presence of ESCC was 0.675 (95% CI 0.622-0.728;
<0.001). According to Youden's index, the best cutoff value was 429.1 pg/mL (sensitivity 0.415 and specificity 0.995). Furthermore, after follow-up, multivariate analyses identified that pathological lymph node metastases were the poorest prognostic factor (HR 1.862, 95% CI 1.093-3.173;
=0.022), followed by serum CKAP4 (HR 1.437, 95% CI 1.025-2.014;
=0.035). When stratified by tertiles of serum CKAP4, subjects in the first tertile presented a mean survival time of 75.4 months (95% CI 68.0-81.9), which decreased significantly in the second tertile (73.8 months, 95% CI 61.4-86.3) and the third tertile (59.9 months, 95% CI 49.8-70.0, log-rank
=8.235;
=0.016).
These results suggested that serum CKAP4 could be a potential biomarker for clinical management of ESCC.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>30538491</pmid><doi>10.2147/OTT.S183790</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1178-6930 |
| ispartof | OncoTargets and therapy, 2018-01, Vol.11, p.8221-8226 |
| issn | 1178-6930 1178-6930 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6251352 |
| source | Taylor & Francis Open Access; DOVE Medical Press Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Analysis Biological markers Cancer metastasis Cancer therapies Carcinoma Care and treatment Chemotherapy Cytoskeleton Disease Endoscopy Enzyme-linked immunosorbent assay Esophageal cancer Gene expression Health risk assessment Hospitals Lung cancer Medical prognosis Medical research Metastasis Original Research Ostomy Prognosis Proteins Proteomics Squamous cell carcinoma Systematic review |
| title | Cytoskeleton-associated protein 4 is a novel serodiagnostic marker for esophageal squamous-cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T21%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cytoskeleton-associated%20protein%204%20is%20a%20novel%20serodiagnostic%20marker%20for%20esophageal%20squamous-cell%20carcinoma&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Chen,%20Lei&rft.date=2018-01-01&rft.volume=11&rft.spage=8221&rft.epage=8226&rft.pages=8221-8226&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S183790&rft_dat=%3Cgale_pubme%3EA583695243%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242635088&rft_id=info:pmid/30538491&rft_galeid=A583695243&rfr_iscdi=true |